AstraZeneca stock heads into Monday meetings after 9M growth
Published on 11/08/2026 at 17:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMonday Meetings Put Pipeline In Focus
- AstraZeneca has scheduled a Berenberg CFO call series and a Redburn roadshow for Monday.
- Nine-month revenue rose 7 percent at constant exchange rates, while full-year guidance was reaffirmed.
- The company said 12 positive Phase III readouts had been reported during the year to date.
AstraZeneca has two investor-facing appointments scheduled for Monday, November 9: a Berenberg CFO Call Series session held virtually and a Redburn roadshow in Boston. Both events are listed in the company's investor relations calendar.
Growth Supports Investor Discussions
The meetings follow AstraZeneca's nine-month and third-quarter results published on October 30. The company reported total revenue of 46.9 billion US dollars for the first nine months, up 7 percent at constant exchange rates. Core earnings per share increased 14 percent to 8.00 US dollars, while full-year guidance for revenue and Core EPS was reaffirmed.
The company's results announcement also highlighted 12 positive Phase III programme readouts during the year to date and a pipeline of 180 projects. For investors, Monday's discussions therefore come against a backdrop of commercial growth, reaffirmed guidance and continued focus on late-stage development.
AstraZeneca stock traded at 167.65 euros on Lang & Schwarz at 17:51 CET on Sunday, November 8, 2026. Investors can follow the real-time quote of AstraZeneca stock on the trading page.
AstraZeneca at a glance
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Market: London Stock Exchange Main Market
- L&S quote: 167.65 euros, Sunday, November 8, 2026, 17:51 CET
- 9M 2026 total revenue: 46.9 billion US dollars, up 7 percent at constant exchange rates
- 9M 2026 Core EPS: 8.00 US dollars, up 14 percent at constant exchange rates
The FTSE 100 provides the relevant UK market backdrop for AstraZeneca investors.
